[Favorable effect of nicotinic acid on lipoprotein normalization with  temporary drug association].
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000188:drug therapy; D001205:Ascorbic Acid / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D004357:Drug Synergism; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D007294:Inositol / Q000627:therapeutic use*; D008074:Lipoproteins / Q000097:blood*; D008875:Middle Aged; D009539:Nicotinic Acids / Q000627:therapeutic use*; D014803:Vitamin B Complex / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D008074:Lipoproteins; D009539:Nicotinic Acids; D014803:Vitamin B Complex; D007294:Inositol; D006493:Heparin; D002784:Cholesterol; D001205:Ascorbic Acid
Migliore effetto dell'acido nicotinico sulla normalizzazione lipoproteica, in una estemporanea associazione medicamentosa.